NKTR
NEKTAR THERAPEUTICS
NEKTAR THERAPEUTICS (NKTR) Stock News
The latest NKTR headlines and market coverage — 1 recent story, updated throughout the day.
- GlobeNewswire Inc.·Bearish
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Nektar Therapeutics faces a securities fraud class action lawsuit after its Phase 2b REZOLVE-AA trial for alopecia areata treatment failed to reach statistical significance. The company allegedly failed to disclose that trial enrollment did not follow protocol standards, leading to a 7.8% stock price decline on December 16, 2025. Investors have until May 5, 2026 to file a lead plaintiff motion.